ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
Phase 2
Terminated
NCT03445000
| Condition | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | ETOP IBCSG Partners Foundation |
|---|
| Status | Terminated |
|---|
| Enrollment | 14 participants |
|---|
| Interventions | Alectinib |
|---|
| Start date | Nov 6, 2018 |
|---|
| Completion date | Mar 31, 2021 |
|---|
| Results posted | Mar 26, 2025 |
|---|
Summary
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
Best Overall Response (BOR)
Evaluated from enrollment through study completion, up to a maximum of 28 months. · Participants
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 0 Participants |
|---|
| Trial Treatment | 9 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
| Trial Treatment | 2 Participants |
|---|
| Trial Treatment | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.